Quanterix announced an exclusive distribution agreement with Sherman Abrams Laboratory to expand access to its LucentAD® Complete blood tests for Alzheimer's disease in the NJ, NY, and CT region. This partnership aims to improve diagnostic access and patient outcomes, representing a moderate positive for Quanterix's market penetration.
Quanterix Corporation has entered into an exclusive distribution agreement with Sherman Abrams Laboratory, effective November 16, 2026. This partnership will make Quanterix's LucentAD® Complete blood tests, which screen for Alzheimer's biomarkers, available through Sherman Abrams Laboratory's physician network in New Jersey, New York, and Connecticut. This is a positive development for Quanterix as it expands the reach of its diagnostic platform, potentially increasing revenue and market share for its Alzheimer's testing solutions. The long-term implication is improved diagnostic access for patients at risk for Alzheimer's in the specified region, which could lead to earlier intervention and better patient outcomes. For traders, this represents an opportunity for Quanterix to grow its diagnostic business, though the impact may be gradual given the effective date is in late 2026.